undamentalytics Newsletter
Sign in

Agilon Health, Inc. (AGL) stock

Add to watchlist

Add holding +

NYSE: AGL NYSE Health Care Services Next results ~November 4, 2026

C Fundamentals grade

Agilon Health, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$200

Valuation models combined (2)

Base case. Range ~$170–$310. Weighted average of 2 models (growth cash-flow model, forward price-to-sales vs peers), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Agilon Health, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders4 buying, 0 selling5 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds130 adding, 40 cuttingOf 38 active managers that changed their stake, 32 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Agilon Health files

Where Agilon Health stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $5.92bn, up 0.3% on a year earlier, against a decline of 2.8% a quarter earlier. That puts it 20 of 21 for growth among the health care services companies we cover. Free-cash-flow margin held at -1.4%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 4 of our 7 financial-health checks. Our valuation models combined value is $140 a share, against a share price of $89.59.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Agilon Health, Inc.'s trailing-twelve-month revenue grew 0.3% year on year, with a free-cash-flow margin of -1.4%. Where it stands out: long-term debt as % of assets of 1.0% ranks 2 of 31 health care services companies we cover.

Current signal Net income rising while operating cash flow falls: TTM net income grew 26.4% while operating cash flow fell 23.8% — earnings and cash are telling different stories.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Growth speeding up. The growth rate is 3.1 points higher than a quarter earlier.

Things to watch

  • Results due soon. Results are expected around 3 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -5.2%: costs exceed revenue.
  • Burning cash. Free cash flow was -1.4% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 166% and a beta of 2.4 against the S&P 500.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
$2.15 against an average estimate of $0.27: beat by 691.5%
Revenue
$1.49bn, up 7.2% on a year earlier
Share reaction
-8.4% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Guidance given
adjusted EBITDA contribution from ACO model entities $25m to $30m (fiscal year 2026)
Next report
November 4, 2026; average EPS estimate -$0.73

Agilon Health's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+2.0%
  • 1 week-4.1%
  • 1 month+3.0%
  • This year+402.9%
  • 1 year+334.8%
  • 5 years-86.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$5.9B
Operating margin
-5.2%
Net margin
-3.9%
EPS (TTM, diluted)
$-14.05

Growth

Revenue growth
+0.3%
Change in growth rate
+3.1 pts
Share count change
+1.8%

Cash

Free cash flow (TTM)
-$85M
FCF margin
-1.4%
Stock pay % of revenue
0.8%

Earnings

Last results
August 5, 2026
Next results (est.)
November 3, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Partnership
  3. Partnership
  4. Product
  5. Announcement
  6. Results
  7. Guidance
  8. Leadership
  9. Results
  10. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Agilon Health, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Agilon Health, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.26 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$170 ~$110–$210 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$41 ~$34–$60 Left out: far from the other models (more than 3x away from their median)
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$310 ~$290–$830 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$200 ~$170–$310 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Agilon Health, Inc. with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025
Share price$675.00$403.50$313.75$47.50$17.23
Market value$251.7bn$164.7bn$128.3bn$19.5bn$7.1bn
+ Net debt (− = net cash)−$991m−$422m−$69m−$153m−$139m
Enterprise value$250.7bn$164.3bn$128.2bn$19.4bn$7.0bn
Multiples
Price / sales 165.4x69.0x29.7x3.2x1.2x
Price / earnings —————
Price / free cash flow —————
EV / EBITDA —————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

12 /100

Weak moat

How hard Agilon Health's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -14.2% of total assets over 6 years.

  • Durability 10 / 20

    Operating margin has been a median -5.0%; its worst year was -23.3%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 6 years, at a median -3.7% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (17 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $1.5bn and EPS of −$0.73 (range −$1.36 to −$0.25) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.79 +93% $5.8bn −2%
Next $2.36 +1592% $6.2bn +7%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −37.9% on 90 days ago. In the last 30 days, 1 analyst raised Agilon Health, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Agilon Health, Inc., last 90 days
−$4.00 −$2.00 $0.00 $2.00 $4.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.88 Current fiscal year, 60 days ago: −$1.60 Current fiscal year, 30 days ago: −$1.79 Current fiscal year, 7 days ago: −$1.79 Current fiscal year, Now: −$1.79 −$1.79 Next fiscal year, 90 days ago: −$0.62 Next fiscal year, 60 days ago: $1.76 Next fiscal year, 30 days ago: $2.40 Next fiscal year, 7 days ago: $2.36 Next fiscal year, Now: $2.36 $2.36

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.88−$0.62
60 days ago −$1.60$1.76
30 days ago −$1.79$2.40
7 days ago −$1.79$2.36
Now −$1.79$2.36

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.27 $2.15 +691.5%
Mar 2026 $0.93 $2.32 +150.0%
Dec 2025 −$6.85 −$8.95 −30.7%
Sept 2025 −$3.36 −$6.40 −90.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 5, 2026
  • Adjusted EBITDA contribution from ACO model entities fiscal year 2026 $25m to $30m Non-GAAP
    “Adjusted EBITDA contribution from ACO model entities is expected to be approximately $25-$30 million for fiscal year 2026.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

15 analysts, Nov 2026
Buy533%
Hold960%
Sell17%

Monthly trend

  1. Nov 20265915
  2. Oct 20265915
  3. Sep 202641116

Counts of recommendations published by analysts covering Agilon Health, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
8.5%
of tradable shares
Days to cover
3.93
at average volume
Short interest, 1 month
−14%
to October 15, 2026
Held by institutions
98%
of shares
Held by insiders
5.0%
of shares
Employees
856
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +334.8%

$19.93 on October 31, 2025 to $86.63

ThenNowEffect
Revenue (last 12 months) $5.9bn $5.9bn +0.3%
P/S multiple 0.1x 0.2x +339.9%
Share count 17m 17m −1.5%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −76.4%

$366.50 on November 3, 2023 to $86.63

ThenNowEffect
Revenue (last 12 months) $3.2bn $5.9bn +85.7%
P/S multiple 1.9x 0.2x −87.0%
Share count 16m 17m −2.2%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
AGL−40%−22%−85%−64%+403%
Industry peers (median)−25%+8%−6%−6%+15%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
AGL50%58%33%33%55%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
AGL−46%−63%−88%−91%−69%
S&P 500−25%−10%−8%−19%−9%

Worst fall since April 15, 2021: 99% from June 18, 2021 to March 31, 2026. Getting back needed a 13569% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$7.91 – $129.84
From 52-week high
−33.3%
vs 50-day average
−1.2%
vs 200-day average
+32.7%
Volatility (1 year)
166%
Beta vs S&P 500
2.41

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±29.2%
After a week
3 up, 9 down
typical move ±40.5%
After a month
3 up, 9 down
typical move ±45.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 −8.4% −0.4% −9.0% −8.8%
May 6, 2026 +126.9% +1.1% +169.3% +262.2%
February 25, 2026 +51.0% +0.3% +77.4% −3.3%
November 4, 2025 −6.9% −0.8% −23.6% −10.1%
August 4, 2025 −48.2% +1.0% −49.2% −29.4%
May 6, 2025 −17.7% −0.4% −34.5% −49.0%
February 25, 2025 −7.7% −0.4% −12.9% +24.2%
November 7, 2024 −36.1% +1.2% −40.6% −22.2%
August 6, 2024 −12.7% +0.2% −13.6% −36.8%
May 7, 2024 +7.5% +0.1% +13.9% +40.8%
February 27, 2024 +3.1% +0.1% −3.1% −7.1%
January 5, 2024 −24.0% +1.6% −38.9% −51.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Agilon Health, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Agilon Health, Inc.
$3B $4B $5B $6B $7B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $3.6B Revenue (TTM), FY23 Q4: $4.3B Revenue (TTM), FY24 Q1: $4.9B Revenue (TTM), FY24 Q2: $5.3B Revenue (TTM), FY24 Q3: $5.6B Revenue (TTM), FY24 Q4: $6.1B Revenue (TTM), FY25 Q1: $6B Revenue (TTM), FY25 Q2: $5.9B Revenue (TTM), FY25 Q3: $5.9B Revenue (TTM), FY25 Q4: $5.9B Revenue (TTM), FY26 Q1: $5.8B Revenue (TTM), FY26 Q2: $5.9B $5.9B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $3.6B
FY23 Q4 $4.3B
FY24 Q1 $4.9B
FY24 Q2 $5.3B
FY24 Q3 $5.6B
FY24 Q4 $6.1B
FY25 Q1 $6B
FY25 Q2 $5.9B
FY25 Q3 $5.9B
FY25 Q4 $5.9B
FY26 Q1 $5.8B
FY26 Q2 $5.9B
Revenue growth, TTM YoY Agilon Health, Inc.
-50% 0% 50% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 67.3% Revenue growth, TTM YoY, FY23 Q4: 80.7% Revenue growth, TTM YoY, FY24 Q1: 74.5% Revenue growth, TTM YoY, FY24 Q2: 65.6% Revenue growth, TTM YoY, FY24 Q3: 54.1% Revenue growth, TTM YoY, FY24 Q4: 40.4% Revenue growth, TTM YoY, FY25 Q1: 23.1% Revenue growth, TTM YoY, FY25 Q2: 11.8% Revenue growth, TTM YoY, FY25 Q3: 5.2% Revenue growth, TTM YoY, FY25 Q4: -2.1% Revenue growth, TTM YoY, FY26 Q1: -2.8% Revenue growth, TTM YoY, FY26 Q2: 0.3% 0.3%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 67.3%
FY23 Q4 80.7%
FY24 Q1 74.5%
FY24 Q2 65.6%
FY24 Q3 54.1%
FY24 Q4 40.4%
FY25 Q1 23.1%
FY25 Q2 11.8%
FY25 Q3 5.2%
FY25 Q4 -2.1%
FY26 Q1 -2.8%
FY26 Q2 0.3%
Operating margin (TTM) Agilon Health, Inc.
-8% -6% -4% -2% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -3.4% Operating margin (TTM), FY23 Q4: -5.4% Operating margin (TTM), FY24 Q1: -4.9% Operating margin (TTM), FY24 Q2: -4.8% Operating margin (TTM), FY24 Q3: -6.2% Operating margin (TTM), FY24 Q4: -4.8% Operating margin (TTM), FY25 Q1: -5.1% Operating margin (TTM), FY25 Q2: -6.4% Operating margin (TTM), FY25 Q3: -6.4% Operating margin (TTM), FY25 Q4: -7.8% Operating margin (TTM), FY26 Q1: -7.5% Operating margin (TTM), FY26 Q2: -5.2% -5.2%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -3.4%
FY23 Q4 -5.4%
FY24 Q1 -4.9%
FY24 Q2 -4.8%
FY24 Q3 -6.2%
FY24 Q4 -4.8%
FY25 Q1 -5.1%
FY25 Q2 -6.4%
FY25 Q3 -6.4%
FY25 Q4 -7.8%
FY26 Q1 -7.5%
FY26 Q2 -5.2%
FCF margin (TTM) Agilon Health, Inc.
-6% -4% -2% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -4.4% FCF margin (TTM), FY23 Q4: -4.0% FCF margin (TTM), FY24 Q1: -3.3% FCF margin (TTM), FY24 Q2: -2.9% FCF margin (TTM), FY24 Q3: -2.7% FCF margin (TTM), FY24 Q4: -1.2% FCF margin (TTM), FY25 Q1: -0.9% FCF margin (TTM), FY25 Q2: -1.2% FCF margin (TTM), FY25 Q3: -1.4% FCF margin (TTM), FY25 Q4: -2.0% FCF margin (TTM), FY26 Q1: -1.1% FCF margin (TTM), FY26 Q2: -1.4% -1.4%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -4.4%
FY23 Q4 -4.0%
FY24 Q1 -3.3%
FY24 Q2 -2.9%
FY24 Q3 -2.7%
FY24 Q4 -1.2%
FY25 Q1 -0.9%
FY25 Q2 -1.2%
FY25 Q3 -1.4%
FY25 Q4 -2.0%
FY26 Q1 -1.1%
FY26 Q2 -1.4%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 794 1,218 1,521 2,388 4,316 6,061 5,933 5,920
EBITDA −65 −43 −358 −92 −212 −268 −435 −281
Operating income −107 −57 −372 −105 −232 −292 −463 −309
Net income −283 −60 −406 −107 −263 −260 −391 −232
Growth (year on year)
Revenue — +53.4% +24.9% +57.0% +80.7% +40.4% −2.1% +0.3%
Margins
EBITDA margin −8.2% −3.5% −23.5% −3.8% −4.9% −4.4% −7.3% −4.8%
Operating margin −13.4% −4.7% −24.5% −4.4% −5.4% −4.8% −7.8% −5.2%
Net margin −35.6% −4.9% −26.7% −4.5% −6.1% −4.3% −6.6% −3.9%
Free-cash-flow margin −13.4% −4.5% −10.2% −6.1% −4.0% −1.2% −2.0% −1.4%
Cash flow
Cash from operations −104 −53 −148 −131 −156 −58 −106 −72
Capital spending 3 2 7 15 16 13 13 13
Free cash flow −107 −55 −155 −146 −172 −71 −119 −85
Stock-based pay 5 7 292 28 69 51 49 47
Free cash flow after stock pay −112 −62 −447 −175 −242 −122 −168 −132
Balance sheet
Cash 139 107 1,040 465 108 188 174 107
Total debt 0 68 49 44 39 35 35 30
Net debt (negative = net cash) −139 −39 −991 −422 −69 −153 −139 −77
Diluted shares 295m 323m 373m 408m 409m 411m 414m —
Returned to shareholders
Buybacks 0 7 0 0 200 0 0 —
Total returned 0 7 0 0 200 0 0 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

4 of 7 checks passed · June 30, 2026
What it owns · $1.6bn
Short-term assets $1.4bnLonger-term assets $173m
What it owes, and who funded it · $1.6bn
Short-term liabilities $1.3bnLonger-term liabilities $51mShareholders' equity $228m
  • Short-term assets cover short-term liabilities $1.4bn of assets due within a year against $1.3bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.4bn short-term assets against $51m of longer-dated liabilities.
  • More cash than debt $107m of cash against $30m of debt.
  • Debt below 40% of shareholders' equity Debt is 13% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 4% to 13% over five years.
  • A year's operating cash flow covers at least 20% of debt −$72m of operating cash flow against $30m of debt.
  • Operating profit covers interest at least five times over Operating income of −$309m against $7m of interest.

From Agilon Health, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Buybacks, last 3 fiscal years
$200M
Diluted share count
+1.8%
year over year

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated AGL OPCH ASTH AMN DGX CHE Median
Revenue, last 12 months $5.9bn $5.7bn $3.8bn $3.4bn $11.8bn $2.7bn $1.2bn
Revenue growth, last 12 months 0.3% 5.9% 58.9% 24.0% 9.1% 5.2% 7.3%
Revenue growth, 3-year average 22.9% 11.3% 43.7% −7.8% 8.4% 6.1% 11.3%
Revenue growth, latest quarter 7.2% 1.9% 48.5% 2.3% 10.0% 10.6% 8.5%
Gross margin — 19.1% 21.5% 27.8% 33.1% 33.5% 27.9%
Operating margin −5.2% 5.9% 2.6% 5.8% 14.6% 13.9% 2.3%
Operating margin, 3-year average −5.5% 6.3% 3.8% 0.5% 13.9% 14.4% 2.3%
Net margin −3.9% 3.7% 1.1% 3.1% 9.5% 10.6% 1.2%
Cash from operations / revenue −1.2% 6.1% 2.8% 13.7% 16.5% 13.6% 6.1%
Free-cash-flow margin −1.4% 5.3% 2.5% 12.8% 11.6% 11.1% 5.1%
Free-cash-flow margin, 3-year average −1.9% 4.7% 3.5% 9.5% 11.7% 11.6% 3.6%
Stock pay / revenue 0.8% 0.7% 1.1% 0.9% 0.7% — 1.1%
Change in share count 1.8% −5.7% 1.8% 2.1% −1.1% −8.3% 0.3%

Median of all 41 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

41 health care services companies
Measure Company Peer median Rank
Revenue growth Growth 0.3% 7.3% 30 of 41
Change in growth rate Growth +3.1pp +1.1pp 12 of 41
Operating margin Profitability -5.2% 2.6% 28 of 40
Net margin Profitability -3.9% 1.2% 26 of 41
Free-cash-flow margin Cash generation -1.4% 5.1% 31 of 40
Stock pay as % of revenue Cash generation 0.8% 0.9% 13 of 35
Long-term debt as % of assets Balance sheet 1.0% 27.7% 2 of 31
Change in share count Balance sheet 1.8% 0.4% 24 of 39

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Medical Services $5.9B 99.8% ▼ 2.1%
Other Operating $11.2M 0.2% ▼ 12.3%

From Agilon Health, Inc.'s 10-K filed February 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$1.7B
Institutions reporting
177
Shares held vs prior quarter
▲ 6.8%
Positions opened / closed
95 / 8

Top buyers and sellers, Q2 2026: 130 institutions bought and 40 sold ; the biggest buyer was Marshall Wace, LLP (+468K shares) and the biggest seller Goldman Sachs Group Inc (−375K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Clayton, Dubilier & Rice, LLC $429M 4.0M 24.9% 0.0%
Morgan Stanley $216M 2.0M 12.5% ▼ 4.2%
North Peak Capital Management, LLC $159M 1.5M 9.2% ▼ 3.9%
Blackrock, Inc. $123M 1.1M 7.1% ▲ 31.3%
AQR Capital Management LLC $74.2M 693K 4.3% ▼ 29.0%
Goldman Sachs Group Inc $73.6M 687K 4.3% ▼ 35.3%
Vanguard Capital Management LLC $56.3M 525K 3.3% ▼ 2.5%
Marshall Wace, LLP $50.2M 468K 2.9% New
Durable Capital Partners LP $47.2M 441K 2.7% New
D. E. Shaw & Co., Inc. $41.8M 390K 2.4% ▼ 47.4%
Charles Schwab Investment Management Inc $37.4M 349K 2.2% ▼ 4.3%
Geode Capital Management, LLC $33.7M 314K 2.0% ▲ 18.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Agilon Health, Inc.'s complete shareholder register. Values are as reported by the filers ; 13 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $351,030 5 trades by 4 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $351,030 net buying
Insider Date Trade Shares Price Value
Shaker Benjamin Chief Markets Officer March 9, 2026 Buy 18,448 — $0
Venkatachaliah Girish Chief Technology Officer March 9, 2026 Buy 18,448 — $0
Zamore Denise Chief Legal Officer March 9, 2026 Buy 5,535 — $0
Shaker Benjamin Chief Markets Officer March 2, 2026 Buy 500,000 $0.60 $300,000
Wulf John William Director November 12, 2025 Buy 81,000 $0.63 $51,030

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 3, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 6, 2026
  • February 25, 2026
  • November 4, 2025
  • August 4, 2025
  • May 6, 2025

Recent SEC filings

Data status

When each part of this page on Agilon Health, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Agilon Health, Inc. in brief

What does Agilon Health, Inc. do?
Agilon Health, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.
What is Agilon Health, Inc.'s stock ticker?
Agilon Health, Inc. trades under the ticker AGL on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Agilon Health, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Agilon Health, Inc. reported revenue of $5.9B, 0.3% higher than a year earlier, according to its SEC filings.
What is Agilon Health, Inc.'s free cash flow?
Agilon Health, Inc.'s free-cash-flow margin is -1.4% of revenue over the trailing twelve months, ranking 31 of the 40 health care services companies we cover.
Who are Agilon Health, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Clayton, Dubilier & Rice, LLC, Morgan Stanley and North Peak Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Agilon Health, Inc.'s market cap?
On December 31, 2025, Agilon Health, Inc.'s market capitalisation was about $7.1B and net debt of -$139M. Market figures come from third-party market data and may be delayed.
How much debt does Agilon Health, Inc. have?
Agilon Health, Inc.'s debt-to-equity ratio is 13.3%, from its latest balance sheet (4.0% five years earlier). The financial health section below sets out its other solvency checks.
Who are Agilon Health, Inc.'s competitors?
In our Health Care Services peer group, the companies closest to Agilon Health, Inc. are Option Care Health, Inc., Astrana Health, Inc., AMN Healthcare Services Inc, Quest Diagnostics and Chemed Corp. The side-by-side comparison below sets their revenue, margins and growth against Agilon Health, Inc.'s.
Are insiders buying or selling Agilon Health, Inc. stock?
Over the last 12 months, Agilon Health, Inc.'s directors and officers reported 5 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Agilon Health, Inc.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Agilon Health, Inc. announces its own schedule.